-
1
-
-
0029765475
-
Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normalman throughout the day
-
Ørskov C, Wettergren A & Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normalman throughout the day. Scandinavian Journal of Gasteroenterology 1996 31 665-670. (doi:10.3109/00365529609009147)
-
(1996)
Scandinavian Journal of Gasteroenterology
, vol.31
, pp. 665-670
-
-
Ørskov, C.1
Wettergren, A.2
Holst, J.J.3
-
2
-
-
0031916924
-
Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
-
Deacon CF, Hughes TE & Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998 47 764-769. (doi:10.2337/diabetes.47. 5.764)
-
(1998)
Diabetes
, vol.47
, pp. 764-769
-
-
Deacon, C.F.1
Hughes, T.E.2
Holst, J.J.3
-
3
-
-
0027419106
-
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations
-
Nauck MA, Bartels E, Ørskov C, Ebert R & Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism 1993 76 912-917. (doi:10.1210/jcem.76.4.8473405)
-
(1993)
Journal of Clinical Endocrinology and Metabolism
, vol.76
, pp. 912-917
-
-
Nauck, M.A.1
Bartels, E.2
Ørskov, C.3
Ebert, R.4
Creutzfeldt, W.5
-
4
-
-
79953871128
-
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes
-
Vardarli I, Nauck MA, Köthe LD, Deacon CF, Holst JJ, Schweizer A & Foley JE. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2011 96 945-954. (doi:10.1210/jc.2010-2178)
-
(2011)
Journal of Clinical Endocrinology and Metabolism
, vol.96
, pp. 945-954
-
-
Vardarli, I.1
Nauck, M.A.2
Köthe, L.D.3
Deacon, C.F.4
Holst, J.J.5
Schweizer, A.6
Foley, J.E.7
-
5
-
-
84893035432
-
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose
-
Vardarli I, Arndt E, Deacon CF, Holst JJ & Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes 2014 63 663-674. (doi:10.2337/db13-0805)
-
(2014)
Diabetes
, vol.63
, pp. 663-674
-
-
Vardarli, I.1
Arndt, E.2
Deacon, C.F.3
Holst, J.J.4
Nauck, M.A.5
-
6
-
-
84864802728
-
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes
-
Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J & Ferrannini E. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2012 97 2818-2826. (doi:10.1210/jc.2012-1205)
-
(2012)
Journal of Clinical Endocrinology and Metabolism
, vol.97
, pp. 2818-2826
-
-
Muscelli, E.1
Casolaro, A.2
Gastaldelli, A.3
Mari, A.4
Seghieri, G.5
Astiarraga, B.6
Chen, Y.7
Alba, M.8
Holst, J.9
Ferrannini, E.10
-
7
-
-
84903517797
-
Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity onset diabetes of the young - Type 2 and type 3
-
In Press
-
Østoft SH, Bagger JI, Hansen T, Pedersen O, Holst JJ, Knop FK & Vilsbøll T. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity onset diabetes of the young - type 2 and type 3. Diabetes 2014. In Press. (doi:10.2337/db13-1878)
-
(2014)
Diabetes
-
-
Østoft, S.H.1
Bagger, J.I.2
Hansen, T.3
Pedersen, O.4
Holst, J.J.5
Knop, F.K.6
Vilsbøll, T.7
-
8
-
-
0018760491
-
Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography
-
Miceli JN, Aravind MK, Cohen SN & Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clinical Chemistry 1979 25 1002-1004.
-
(1979)
Clinical Chemistry
, vol.25
, pp. 1002-1004
-
-
Miceli, J.N.1
Aravind, M.K.2
Cohen, S.N.3
Done, A.K.4
-
9
-
-
0035008133
-
Gastric emptying: The validity of the paracetamol absorption test adjusted for individual pharmacokinetics
-
Medhus AW, Lofthus CM, Bredesen J & Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterology and Motility 2001 13 179-185. (doi:10.1046/j.1365-2982.2001.00249.x)
-
(2001)
Neurogastroenterology and Motility
, vol.13
, pp. 179-185
-
-
Medhus, A.W.1
Lofthus, C.M.2
Bredesen, J.3
Husebye, E.4
-
10
-
-
0028281773
-
Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide i in humans
-
Ørskov C, Rabenhøj L, Wettergren A, Kofod H & Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes 1994 43 535-539. (doi:10.2337/diab. 43.4.535)
-
(1994)
Diabetes
, vol.43
, pp. 535-539
-
-
Ørskov, C.1
Rabenhøj, L.2
Wettergren, A.3
Kofod, H.4
Holst, J.J.5
-
11
-
-
0021211623
-
The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
-
Krarup T & Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides 1984 9 35-46. (doi:10.1016/0167-0115(84)90005-3)
-
(1984)
Regulatory Peptides
, vol.9
, pp. 35-46
-
-
Krarup, T.1
Holst, J.J.2
-
12
-
-
0033766716
-
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
-
Deacon CF, Nauck MA, Meier J, Hucking K & Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Journal of Clinical Endocrinology and Metabolism 2000 85 3575-3581. (doi:10.1210/jcem.85.10.6855)
-
(2000)
Journal of Clinical Endocrinology and Metabolism
, vol.85
, pp. 3575-3581
-
-
Deacon, C.F.1
Nauck, M.A.2
Meier, J.3
Hucking, K.4
Holst, J.J.5
-
13
-
-
4244188766
-
New highly specific immunoassays for glucagon-like peptide-1 (GLP-1) (Abstract)
-
Wilken M, Larsen F, Buckley D & Holst J. New highly specific immunoassays for glucagon-like peptide-1 (GLP-1) (Abstract). Diabetologia 1999 42 (Suppl 1) A196.
-
(1999)
Diabetologia
, vol.42
, pp. A196
-
-
Wilken, M.1
Larsen, F.2
Buckley, D.3
Holst, J.4
-
14
-
-
0026027919
-
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
-
Ørskov C, Jeppesen J, Madsbad S & Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. Journal of Clinical Investigation 1991 87 415-423. (doi:10.1172/JCI115012)
-
(1991)
Journal of Clinical Investigation
, vol.87
, pp. 415-423
-
-
Ørskov, C.1
Jeppesen, J.2
Madsbad, S.3
Holst, J.J.4
-
15
-
-
0026504160
-
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance
-
Van Cauter E, Mestrez F, Sturis J & Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992 41 368-377. (doi:10.2337/diabetes.41.3.368)
-
(1992)
Diabetes
, vol.41
, pp. 368-377
-
-
Van Cauter, E.1
Mestrez, F.2
Sturis, J.3
Polonsky, K.S.4
-
16
-
-
0022461548
-
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
-
Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R & Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Journal of Clinical Endocrinology and Metabolism 1986 63 492-498. (doi:10.1210/jcem-63-2-492)
-
(1986)
Journal of Clinical Endocrinology and Metabolism
, vol.63
, pp. 492-498
-
-
Nauck, M.A.1
Homberger, E.2
Siegel, E.G.3
Allen, R.C.4
Eaton, R.P.5
Ebert, R.6
Creutzfeldt, W.7
-
17
-
-
77949822066
-
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes
-
Hare KJ, Vilsbøll T, Holst JJ & Knop FK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology. Endocrinology and Metabolism 2010 298 E832-E837. (doi:10.1152/ajpendo.00700.2009)
-
(2010)
American Journal of Physiology. Endocrinology and Metabolism
, vol.298
, pp. E832-E837
-
-
Hare, K.J.1
Vilsbøll, T.2
Holst, J.J.3
Knop, F.K.4
-
18
-
-
84899091067
-
Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin
-
Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, Langdon RB & Kauh EA. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy 2013 4 431-442. (doi:10.1007/s13300-013-0045-8)
-
(2013)
Diabetes Therapy
, vol.4
, pp. 431-442
-
-
Tatosian, D.A.1
Guo, Y.2
Schaeffer, A.K.3
Gaibu, N.4
Popa, S.5
Stoch, A.6
Langdon, R.B.7
Kauh, E.A.8
-
19
-
-
33749871472
-
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
-
Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2006 91 4612-4619. (doi:10.1210/jc.2006-1009)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, pp. 4612-4619
-
-
Herman, G.A.1
Bergman, A.2
Stevens, C.3
Kotey, P.4
Yi, B.5
Zhao, P.6
Dietrich, B.7
Golor, G.8
Schrodter, A.9
Keymeulen, B.10
-
20
-
-
35948941910
-
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
-
El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D & Nauck MA. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. Journal of Clinical Endocrinology and Metabolism 2007 92 4165-4171. (doi:10.1210/jc.2006-1932)
-
(2007)
Journal of Clinical Endocrinology and Metabolism
, vol.92
, pp. 4165-4171
-
-
El-Ouaghlidi, A.1
Rehring, E.2
Holst, J.J.3
Schweizer, A.4
Foley, J.5
Holmes, D.6
Nauck, M.A.7
-
21
-
-
63049113329
-
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin
-
Migoya EM, Stevens CH, Bergman AJ, Luo WL, Lasseter KC, Dilzer SC, Davies MJ, Wagner JA & Herman GA. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Canadian Journal of Clinical Pharmacology 2009; 16: e165-e170.
-
(2009)
Canadian Journal of Clinical Pharmacology
, vol.16
, pp. e165-e170
-
-
Migoya, E.M.1
Stevens, C.H.2
Bergman, A.J.3
Luo, W.L.4
Lasseter, K.C.5
Dilzer, S.C.6
Davies, M.J.7
Wagner, J.A.8
Herman, G.A.9
-
22
-
-
0036188070
-
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
-
Deacon CF, Wamberg S, Bie P, Hughes TE & Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. Journal of Endocrinology 2002 172 355-362. (doi:10.1677/joe.0.1720355)
-
(2002)
Journal of Endocrinology
, vol.172
, pp. 355-362
-
-
Deacon, C.F.1
Wamberg, S.2
Bie, P.3
Hughes, T.E.4
Holst, J.J.5
-
23
-
-
78449274342
-
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
-
Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clinical Pharmacology and Therapeutics 2010 88 801-808. (doi:10.1038/clpt. 2010.184)
-
(2010)
Clinical Pharmacology and Therapeutics
, vol.88
, pp. 801-808
-
-
Migoya, E.M.1
Bergeron, R.2
Miller, J.L.3
Snyder, R.N.4
Tanen, M.5
Hilliard, D.6
Weiss, B.7
Larson, P.8
Gutierrez, M.9
Jiang, G.10
-
24
-
-
58149177392
-
Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers
-
Hu P, Yin Q, Deckert F, Jiang J, Liu D, Kjems L, Dole WP & He YL. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. Journal of Clinical Pharmacology 2009 49 39-49. (doi:10.1177/0091270008325152)
-
(2009)
Journal of Clinical Pharmacology
, vol.49
, pp. 39-49
-
-
Hu, P.1
Yin, Q.2
Deckert, F.3
Jiang, J.4
Liu, D.5
Kjems, L.6
Dole, W.P.7
He, Y.L.8
-
25
-
-
77954866977
-
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
-
Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology 2010 73 189-196. (doi:10.1111/j.1365-2265.2009.03764.x)
-
(2010)
Clinical Endocrinology
, vol.73
, pp. 189-196
-
-
Bock, G.1
Dalla Man, C.2
Micheletto, F.3
Basu, R.4
Giesler, P.D.5
Laugen, J.6
Deacon, C.F.7
Holst, J.J.8
Toffolo, G.9
Cobelli, C.10
-
26
-
-
38149096290
-
Effects of the dipeptidyl peptidase- IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
-
Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E & Baron MA. Effects of the dipeptidyl peptidase- IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008 31 30-35. (doi:10.2337/dc07-1616)
-
(2008)
Diabetes Care
, vol.31
, pp. 30-35
-
-
Rosenstock, J.1
Foley, J.E.2
Rendell, M.3
Landin-Olsson, M.4
Holst, J.J.5
Deacon, C.F.6
Rochotte, E.7
Baron, M.A.8
-
27
-
-
84877600473
-
Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects
-
Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A & Ahren B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes, Obesity & Metabolism 2013 15 531-537. (doi:10.1111/dom. 12062)
-
(2013)
Diabetes, Obesity & Metabolism
, vol.15
, pp. 531-537
-
-
Ohlsson, L.1
Alsalim, W.2
Carr, R.D.3
Tura, A.4
Pacini, G.5
Mari, A.6
Ahren, B.7
-
28
-
-
77957741412
-
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men
-
Aoki K, Masuda K, Miyazaki T, Togashi Y & Terauchi Y. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocrine Journal 2010 57 667-672. (doi:10.1507/endocrj.K10E-103)
-
(2010)
Endocrine Journal
, vol.57
, pp. 667-672
-
-
Aoki, K.1
Masuda, K.2
Miyazaki, T.3
Togashi, Y.4
Terauchi, Y.5
-
29
-
-
84897445343
-
Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels
-
Aoki K, Kamiyama H, Masuda K, Kamiko K, Noguchi Y, Tajima K & Terauchi Y. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. Endocrine Journal 2014 61 249-256. (doi:10.1507/endocrj.EJ13-0399)
-
(2014)
Endocrine Journal
, vol.61
, pp. 249-256
-
-
Aoki, K.1
Kamiyama, H.2
Masuda, K.3
Kamiko, K.4
Noguchi, Y.5
Tajima, K.6
Terauchi, Y.7
-
30
-
-
84905019254
-
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin
-
In press
-
Wu T, Ma J, Bound MJ, Checklin H, Deacon CF, Jones KL, HorowitzM& Rayner CK. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin. Diabetes 2014. In press. (doi:10.2337/db13-1627)
-
(2014)
Diabetes
-
-
Wu, T.1
Ma, J.2
Bound, M.J.3
Checklin, H.4
Deacon, C.F.5
Jones, K.L.6
Horowitz, M.7
Rayner, C.K.8
-
31
-
-
0027391607
-
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
-
Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R & CreutzfeldtW. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 1993 91 301-307. (doi:10.1172/JCI116186)
-
(1993)
Journal of Clinical Investigation
, vol.91
, pp. 301-307
-
-
Nauck, M.A.1
Heimesaat, M.M.2
Ørskov, C.3
Holst, J.J.4
Ebert, R.5
Creutzfeldt, W.6
-
32
-
-
73249122913
-
Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus
-
Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ & Vilsboll T. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2009 94 4679-4687. (doi:10.1210/jc.2009-0921)
-
(2009)
Journal of Clinical Endocrinology and Metabolism
, vol.94
, pp. 4679-4687
-
-
Hare, K.J.1
Knop, F.K.2
Asmar, M.3
Madsbad, S.4
Deacon, C.F.5
Holst, J.J.6
Vilsboll, T.7
-
33
-
-
82255185915
-
Glucose-dependent insulinotropic polypeptide: A bifunctional glucosedependent regulator of glucagon and insulin secretion in humans
-
Christensen M, Vedtofte L, Holst JJ, Vilsboll T & Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucosedependent regulator of glucagon and insulin secretion in humans. Diabetes 2011 60 3103-3109. (doi:10.2337/db11-0979)
-
(2011)
Diabetes
, vol.60
, pp. 3103-3109
-
-
Christensen, M.1
Vedtofte, L.2
Holst, J.J.3
Vilsboll, T.4
Knop, F.K.5
-
34
-
-
0038121744
-
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
-
Vilsbøll T, Krarup T, Madsbad S & Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides 2003 114 115-121. (doi:10.1016/S0167- 0115(03)00111-3)
-
(2003)
Regulatory Peptides
, vol.114
, pp. 115-121
-
-
Vilsbøll, T.1
Krarup, T.2
Madsbad, S.3
Holst, J.J.4
-
35
-
-
0037207057
-
The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum
-
Hansen L & Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regulatory Peptides 2002 110 39-45. (doi:10.1016/S0167-0115(02)00157-X)
-
(2002)
A Duodeno-ileal Loop? Regulatory Peptides
, vol.110
, pp. 39-45
-
-
Hansen, L.1
Holst, J.J.2
-
36
-
-
84867581999
-
Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucosedependent insulinotropic polypeptide from intestinal K cells in rodents
-
Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib AM, Evans ML, Gribble FM & Reimann F. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucosedependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 2012 55 3094-3103. (doi:10.1007/s00125-012- 2663-5)
-
(2012)
Diabetologia
, vol.55
, pp. 3094-3103
-
-
Moss, C.E.1
Marsh, W.J.2
Parker, H.E.3
Ogunnowo-Bada, E.4
Riches, C.H.5
Habib, A.M.6
Evans, M.L.7
Gribble, F.M.8
Reimann, F.9
-
37
-
-
84879189059
-
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
-
Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Vilsbøll T, Knop FK et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013 304 G1117-G1127. (doi:10.1152/ajpgi.00035.2013)
-
(2013)
American Journal of Physiology. Gastrointestinal and Liver Physiology
, vol.304
, pp. G1117-G1127
-
-
Plamboeck, A.1
Veedfald, S.2
Deacon, C.F.3
Hartmann, B.4
Wettergren, A.5
Svendsen, L.B.6
Meisner, S.7
Hovendal, C.8
Vilsbøll, T.9
Knop, F.K.10
|